Neurocrine Biosciences annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Neurocrine Biosciences Revenue Growth & History (NBIX)
Neurocrine Biosciences reported $2.86B in revenue for fiscal 2025, an increase of 21.45% from the previous fiscal year.
View full Neurocrine Biosciences company overviewNeurocrine Biosciences annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.86B | $505.2M | +21.45% |
| 2024 | 2024-12-31 | $2.36B | $468.2M | +24.81% |
| 2023 | 2023-12-31 | $1.89B | $398.4M | +26.76% |
| 2022 | 2022-12-31 | $1.49B | $355.2M | +31.34% |
| 2021 | 2021-12-31 | $1.13B | $87.6M | +8.38% |
| 2020 | 2020-12-31 | $1.05B | $257.8M | +32.71% |
| 2019 | 2019-12-31 | $788.1M | $336.9M | +74.67% |
| 2018 | 2018-12-31 | $451.2M | $289.6M | +179.16% |
| 2017 | 2017-12-31 | $161.6M | $146.6M | +977.51% |
| 2016 | 2016-12-31 | $15.0M | −$4.8M | −24.12% |
| 2015 | 2015-12-31 | $19.8M | $19.8M | — |
| 2014 | 2014-12-31 | $0 | −$2.9M | −100.00% |
| 2013 | 2013-12-31 | $2.9M | −$50.2M | −94.51% |
| 2012 | 2012-12-31 | $53.1M | −$24.3M | −31.36% |
| 2011 | 2011-12-31 | $77.4M | $43.9M | +131.08% |
| 2010 | 2010-12-31 | $33.5M | $30.5M | +1034.47% |
| 2009 | 2009-12-31 | $3.0M | — | — |
Neurocrine Biosciences quarterly revenue
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $959.0M | $271.5M | +39.49% |
| Q1 2026 | 2026-03-31 | $814.5M | $241.9M | +42.25% |
| Q4 2025 | 2025-12-31 | $805.5M | $177.8M | +28.33% |
| Q3 2025 | 2025-09-30 | $794.9M | $172.8M | +27.78% |
| Q2 2025 | 2025-06-30 | $687.5M | $97.3M | +16.49% |
| Q1 2025 | 2025-03-31 | $572.6M | $57.3M | +11.12% |
| Q4 2024 | 2024-12-31 | $627.7M | $112.5M | +21.84% |
| Q3 2024 | 2024-09-30 | $622.1M | $123.3M | +24.72% |
| Q2 2024 | 2024-06-30 | $590.2M | $137.5M | +30.37% |
| Q1 2024 | 2024-03-31 | $515.3M | $94.9M | +22.57% |
| Q4 2023 | 2023-12-31 | $515.2M | $103.2M | +25.05% |
| Q3 2023 | 2023-09-30 | $498.8M | $110.9M | +28.59% |
| Q2 2023 | 2023-06-30 | $452.7M | $74.5M | +19.70% |
| Q1 2023 | 2023-03-31 | $420.4M | $109.8M | +35.35% |
| Q4 2022 | 2022-12-31 | $412.0M | $100.0M | +32.05% |
| Q3 2022 | 2022-09-30 | $387.9M | $91.9M | +31.05% |
| Q2 2022 | 2022-06-30 | $378.2M | $89.3M | +30.91% |
| Q1 2022 | 2022-03-31 | $310.6M | $74.0M | +31.28% |
| Q4 2021 | 2021-12-31 | $312.0M | $64.1M | +25.86% |
| Q3 2021 | 2021-09-30 | $296.0M | $37.5M | +14.51% |
| Q2 2021 | 2021-06-30 | $288.9M | −$13.5M | −4.46% |
| Q1 2021 | 2021-03-31 | $236.6M | −$500,000 | −0.21% |
| Q4 2020 | 2020-12-31 | $247.9M | $3.8M | +1.56% |
| Q3 2020 | 2020-09-30 | $258.5M | $36.4M | +16.39% |
| Q2 2020 | 2020-06-30 | $302.4M | $118.9M | +64.80% |
| Q1 2020 | 2020-03-31 | $237.1M | $98.7M | +71.32% |
| Q4 2019 | 2019-12-31 | $244.1M | $112.6M | +85.64% |
| Q3 2019 | 2019-09-30 | $222.1M | $70.3M | +46.35% |
| Q2 2019 | 2019-06-30 | $183.5M | $86.6M | +89.36% |
| Q1 2019 | 2019-03-31 | $138.4M | $67.3M | +94.69% |
| Q4 2018 | 2018-12-31 | $131.5M | $37.0M | +39.12% |
| Q3 2018 | 2018-09-30 | $151.8M | $91.0M | +149.71% |
| Q2 2018 | 2018-06-30 | $96.9M | $90.6M | +1429.68% |
| Q1 2018 | 2018-03-31 | $71.1M | $71.1M | — |
| Q4 2017 | 2017-12-31 | $94.5M | $94.5M | — |
| Q3 2017 | 2017-09-30 | $60.8M | $60.8M | — |
| Q2 2017 | 2017-06-30 | $6.3M | $6.3M | — |
| Q1 2017 | 2017-03-31 | $0 | −$15.0M | −100.00% |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $0 | $0 | — |
| Q1 2016 | 2016-03-31 | $15.0M | −$4.8M | −24.12% |
| Q4 2015 | 2015-12-31 | $0 | $0 | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q2 2015 | 2015-06-30 | $0 | $0 | — |
| Q1 2015 | 2015-03-31 | $19.8M | $19.8M | — |
| Q4 2014 | 2014-12-31 | $0 | −$730,000 | −100.00% |
| Q3 2014 | 2014-09-30 | $0 | −$729,000 | −100.00% |
| Q2 2014 | 2014-06-30 | $0 | −$730,000 | −100.00% |
| Q1 2014 | 2014-03-31 | $0 | −$730,000 | −100.00% |
| Q4 2013 | 2013-12-31 | $730,000 | −$21.2M | −96.67% |
| Q3 2013 | 2013-09-30 | $729,000 | −$8.6M | −92.21% |
| Q2 2013 | 2013-06-30 | $730,000 | −$9.8M | −93.09% |
| Q1 2013 | 2013-03-31 | $730,000 | −$10.5M | −93.52% |
| Q4 2012 | 2012-12-31 | $21.9M | $10.8M | +97.54% |
| Q3 2012 | 2012-09-30 | $9.4M | −$32.3M | −77.53% |
| Q2 2012 | 2012-06-30 | $10.6M | −$1.6M | −13.06% |
| Q1 2012 | 2012-03-31 | $11.3M | −$1.2M | −9.95% |
| Q4 2011 | 2011-12-31 | $11.1M | — | — |
| Q3 2011 | 2011-09-30 | $41.6M | $27.2M | +188.16% |
| Q2 2011 | 2011-06-30 | $12.2M | $7.5M | +161.84% |
| Q1 2011 | 2011-03-31 | $12.5M | — | — |
| Q3 2010 | 2010-09-30 | $14.4M | — | — |
| Q2 2010 | 2010-06-30 | $4.6M | — | — |
Neurocrine Biosciences revenue growth trends
Over the last five reported fiscal years, revenue grew from $1.05B to $2.86B, a compound annual growth rate of 22.29%. Neurocrine Biosciences's latest reported quarter, Q2 2026, generated $959.0M in revenue, an increase of 39.49% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Neurocrine Biosciences source filings ↗